LINC02523: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02523

NCBI ID: G643623

LINC02523

Other Name(s): long intergenic non-protein coding RNA 2523 | Long intergenic non-protein coding RNA 2523

LINC02523: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC02523 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique structure, length, and expression pattern, which has caught the attention of researchers due to its potential involvement in various biological processes . Although the primary function of LINC02523 is not well understood, its expression patterns and involvement in gene regulation have been well-studied.

The discovery and characterization of LINC02523

LINC02523 was first identified using transcriptomics experiments in the human proteome. It was found to have a unique expression pattern, with high expression in the liver and moderate expression in the other tissues. The gene encoding LINC02523 has a length of approximately 2.5 kilobases (kb) and contains 18 exons.

Function and regulation

LINC02523 is involved in the regulation of gene expression, specifically in the control of cell cycle progression and the regulation of cellular processes such as cell adhesion, migration, and invasion. It is well-established that LINC02523 plays a role in the regulation of cell cycle progression, and it has been shown to directly interact with the protein kinase A-TAT3.

Additionally, LINC02523 has been shown to be involved in the regulation of cellular adhesion and migration. It has been shown to interact with the adhesion molecule E-cadherin and the migration-promoting protein, chemokine S-phase myeloma associated protein (SMAP).

Mutational studies have also identified several potential drug targets for LINC02523. The specific target sites for these studies were identified by bioinformatics analysis of the LINC02523 gene and its protein product.

Drug targeting

One of the potential drug targets for LINC02523 is the PI3K/AKT signaling pathway. This pathway is known to play a role in the regulation of cellular processes such as cell survival, angiogenesis, and inflammation. LINC02523 has been shown to interact with the protein kinase A-TAT3, which is a key regulator of the PI3K/AKT signaling pathway.

Investigations have shown that LINC02523 can inhibit the activity of A-TAT3 and that this inhibition can lead to the inhibition of cell proliferation and the inhibition of angiogenesis. This suggests that LINC02523 may be an effective drug target for the treatment of various diseases associated with the PI3K/AKT signaling pathway, such as cancer, cardiovascular disease, and neurodegenerative diseases.

Another potential drug target for LINC02523 is the TGF-β signaling pathway. This pathway is involved in the regulation of cellular processes such as cell growth, differentiation, and inflammation. LINC02523 has been shown to interact with the transcription factor, Smad2.

Investigations have shown that LINC02523 can inhibit the activity of Smad2 and that this inhibition can lead to the inhibition of TGF-β signaling. This suggests that LINC02523 may be an effective drug target for the treatment of various diseases associated with TGF-β signaling, such as cancer, neurodegenerative diseases, and autoimmune diseases.

Conclusion

In conclusion, LINC02523 is a long non-coding RNA that has been identified in various organisms, including humans. Its unique structure, length, and expression pattern have caught the attention of researchers due to its potential involvement in various biological processes. Further studies have shown that LINC02523 is involved in the regulation of cell cycle progression, cellular adhesion and migration, and the PI3K/AKT and TGF-β signaling pathways. These findings suggest that LINC02523 may be an attractive drug target for the treatment of various diseases associated with these signaling pathways. Further research is needed to fully understand the function and regulation of LINC02523 and to determine its potential as a drug target.

Protein Name: Long Intergenic Non-protein Coding RNA 2523

The "LINC02523 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02523 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets